Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<ResearchStudy xmlns="http://hl7.org/fhir">
<id value="399864"/>
<meta>
<versionId value="5"/>
<lastUpdated value="2025-09-14T18:44:20.424Z"/>
<profile
value="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/m11-research-study-profile"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/study-design"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/study-registry-record"/>
</meta>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ResearchStudy IGBJ-ResearchStudy</b></p><p><a name="IGBJ-ResearchStudy"> </a><a name="hcIGBJ-ResearchStudy"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-m11-research-study-profile.html">M11 Research Study</a></p></div><p><b>Narrative Elements</b>: <a href="Composition-IGBJ-Narrative-1.3.html">Composition IGBJ Protocol Narrative 1.3</a></p><p><b>Narrative Elements</b>: <a href="Composition-IGBJ-Narrative-2.1.html">Composition IGBJ Protocol Narrative 2.1</a></p><p><b>Narrative Elements</b>: <a href="Composition-IGBJ-Narrative-5.1.html">Composition IGBJ Protocol Narrative 5.1</a></p><p><b>Narrative Elements</b>: <a href="Composition-IGBJ-Narrative-9.html">Composition IGBJ Protocol Narrative 9</a></p><blockquote><p><b>M11_ProtocolAmendment</b></p><blockquote><p><b>url</b></p>scope</blockquote><p><b>value</b>: C217026</p><blockquote><p><b>url</b></p><a href="http://hl7.org/fhir/R5/valueset-country.html">Country ValueSet</a></blockquote><p><b>value</b>: DE</p><blockquote><p><b>url</b></p><a href="http://hl7.org/fhir/R5/valueset-country.html">Country ValueSet</a></blockquote><p><b>value</b>: GB</p><blockquote><p><b>url</b></p>region</blockquote><p><b>value</b>: AU-NSW</p><blockquote><p><b>url</b></p>site</blockquote><p><b>value</b>: <code>https://example.org/site-identifier</code>/sss</p><blockquote><p><b>url</b></p>approvalDate</blockquote><p><b>value</b>: 2017-12-05</p><blockquote><p><b>url</b></p>signature</blockquote><p><b>value</b>: No display for Signature (data: 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)</p><blockquote><p><b>url</b></p>signatureURL</blockquote><p><b>value</b>: https://somelocation</p><blockquote><p><b>url</b></p>signatureMethod</blockquote><p><b>value</b>: electronic and wet ink copy</p><p><b>scope</b>: C41065</p><p><b>number</b>: 234</p><blockquote><p><b>url</b></p><a href="StructureDefinition-ResearchStudyStudyAmendmentScopeImpact.html">ResearchStudyStudyAmendmentScopeImpact</a></blockquote><p><b>scope</b>: C68846</p><p><b>number</b>: 983</p><blockquote><p><b>url</b></p><a href="StructureDefinition-ResearchStudyStudyAmendmentScopeImpact.html">ResearchStudyStudyAmendmentScopeImpact</a></blockquote><blockquote><p><b>url</b></p>primaryReason</blockquote><p><b>value</b>: <span title="Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C218490}">Regulatory Agency Request To Amend</span></p><blockquote><p><b>url</b></p>secondaryReason</blockquote><p><b>value</b>: <span title="Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C218494}">Manufacturing Change</span></p><blockquote><p><b>url</b></p><a href="http://hl7.org/fhir/R5/codesystem-example-summary.html">summary</a></blockquote><p><b>value</b>: Regulator required manufacturing chanage.</p><blockquote><p><b>url</b></p>substantialImpactSafety</blockquote><p><b>value</b>: C49488</p><blockquote><p><b>url</b></p>substantialImpactSafetyComment</blockquote><p><b>value</b>: Specifically implemented to decrease safety risks.</p><blockquote><p><b>url</b></p>substantialImpactReliability</blockquote><p><b>value</b>: C17998</p><blockquote><p><b>url</b></p>substantialImpactReliabilityComment</blockquote><p><b>value</b>: ccc</p><p><b>detail</b>: amendment one</p><p><b>rationale</b>: clarification</p><p><b>section</b>: <span title="Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C218515}">1.1 Protocol Synopsis</span></p><blockquote><p><b>url</b></p><a href="StructureDefinition-protocol-amendment-detail.html">ResearchStudyStudyAmendmentDetails</a></blockquote><p><b>detail</b>: amendment two</p><p><b>rationale</b>: exclude regular drinkers</p><p><b>section</b>: <span title="Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C218550}">5.3 Exclusion Criteria</span></p><blockquote><p><b>url</b></p><a href="StructureDefinition-protocol-amendment-detail.html">ResearchStudyStudyAmendmentDetails</a></blockquote><blockquote><p><b>url</b></p>rationale</blockquote><p><b>value</b>: Updates to address safety concern & align with product guidelines.</p><blockquote><p><b>url</b></p>description</blockquote><p><b>value</b>: Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus has been amended. The new protocol is indicated by Amendment (a) and will be used to conduct the study in place of any preceding version of the protocol. The overall changes and rationale for the changes made to this protocol are as follows: • An exclusion criterion for patients with retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage induced by hypoglycemia. • The GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary of Product Characteristics (2015).</p></blockquote><p><b>ResearchStudySponsorConfidentialityStatement</b>: All data is confidential</p><p><b>identifier</b>: Regulatory Agency Identifier/NCT03421379 (use: official, ), Sponsor Identifier/I8R-JE-IGBJ (use: usual, ), Amendment Identifier/I8R-JE-IGBJ(a) (use: usual, )</p><p><b>version</b>: (a)</p><p><b>title</b>: A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus</p><h3>Labels</h3><table class="grid"><tbody><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Value</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/title-type short-title}">Short title</span></td><td>A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus</td></tr></tbody></table><p><b>date</b>: 2017-12-05</p><p><b>status</b>: Draft</p><p><b>phase</b>: <span title="Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C15602}">Phase 3</span></p><h3>Focus</h3><table class="grid"><tbody><tr><td style="display: none">-</td><td><b>Reference</b></td></tr><tr><td style="display: none">*</td><td><a href="MedicinalProductDefinition-IGBJ-MedicinalProduct.html">MedicinalProductDefinition: identifier = Sponsor Investigational Product Code: LY900018</a></td></tr></tbody></table><p><b>condition</b>: <span title="Codes:{http://snomed.info/sct 1137328006}">Iatrogenic hypoglycaemia</span></p></div>
</text>
<contained>
<EvidenceVariable>
<id value="NCT03421379-drug------glucagon-nasal-powder"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
</meta>
<name value="NCT03421379_drug______glucagon_nasal_powder"/>
<title value="Glucagon Nasal Powder"/>
<status value="active"/>
<description value="Administered intranasally"/>
<note>
<text value="suggested alternative name: LY900018"/>
</note>
<handling value="boolean"/>
<classifier>
<text value="Intervention Type: DRUG"/>
</classifier>
</EvidenceVariable>
</contained>
<contained>
<EvidenceVariable>
<id value="NCT03421379-drug------glucagon-hydrochloride-solution"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
</meta>
<name value="NCT03421379_drug______glucagon_hydrochloride_solution"/>
<title value="Glucagon Hydrochloride Solution"/>
<status value="active"/>
<description value="Administered IM"/>
<note>
<text value="suggested alternative name: GlucaGen®"/>
</note>
<handling value="boolean"/>
<classifier>
<text value="Intervention Type: DRUG"/>
</classifier>
</EvidenceVariable>
</contained>
<contained>
<Group>
<id value="NCT03421379-comparison-group-0"/>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Computable Publishing®: [System]-to-FEvIR Converter"/>
</valueContactDetail>
</extension>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-comparison-group-0"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<title value="NCT03421379 Comparison Group: Glucagon Nasal Powder"/>
<status value="active"/>
<description
value="A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally."/>
<membership value="conceptual"/>
<code>
<text value="Experimental"/>
</code>
<characteristic>
<code>
<text value="Exposed to"/>
</code>
<valueReference>
<reference value="#NCT03421379-drug------glucagon-nasal-powder"/>
<type value="EvidenceVariable"/>
<display value="Drug: Glucagon Nasal Powder"/>
</valueReference>
<exclude value="false"/>
</characteristic>
</Group>
</contained>
<contained>
<Group>
<id value="NCT03421379-comparison-group-1"/>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Computable Publishing®: [System]-to-FEvIR Converter"/>
</valueContactDetail>
</extension>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-comparison-group-1"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<title
value="NCT03421379 Comparison Group: Glucagon Hydrochloride Solution"/>
<status value="active"/>
<description
value="A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)"/>
<membership value="conceptual"/>
<code>
<text value="Active Comparator"/>
</code>
<characteristic>
<code>
<text value="Exposed to"/>
</code>
<valueReference>
<reference
value="#NCT03421379-drug------glucagon-hydrochloride-solution"/>
<type value="EvidenceVariable"/>
<display value="Drug: Glucagon Hydrochloride Solution"/>
</valueReference>
<exclude value="false"/>
</characteristic>
</Group>
</contained>
<contained>
<Location>
<id value="NCT03421379-Location-0"/>
<name
value="For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."/>
<address>
<city value="Fukuoka"/>
<postalCode value="812-0025"/>
<country value="Japan"/>
</address>
<position>
<longitude value="130.41667"/>
<latitude value="33.6"/>
</position>
</Location>
</contained>
<contained>
<Location>
<id value="NCT03421379-Location-1"/>
<name
value="For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."/>
<address>
<city value="Tokyo"/>
<postalCode value="130-0004"/>
<country value="Japan"/>
</address>
<position>
<longitude value="139.69171"/>
<latitude value="35.6895"/>
</position>
</Location>
</contained>
<contained>
<Location>
<id value="NCT03421379-Location-2"/>
<name
value="For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician."/>
<address>
<city value="Tokyo"/>
<postalCode value="162-0053"/>
<country value="Japan"/>
</address>
<position>
<longitude value="139.69171"/>
<latitude value="35.6895"/>
</position>
</Location>
</contained>
<contained>
<Location>
<id value="NCT03421379-Location-3"/>
<name
value="For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."/>
<address>
<city value="Tokyo"/>
<postalCode value="169-0073"/>
<country value="Japan"/>
</address>
<position>
<longitude value="139.69171"/>
<latitude value="35.6895"/>
</position>
</Location>
</contained>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/narrative-elements">
<valueReference>🔗
<reference value="Composition/399865"/>
<type value="Composition"/>
<display value="IGBJ Protocol Narrative 1.3"/>
</valueReference>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/narrative-elements">
<valueReference>🔗
<reference value="Composition/399866"/>
<type value="Composition"/>
<display value="IGBJ Protocol Narrative 2.1"/>
</valueReference>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/narrative-elements">
<valueReference>🔗
<reference value="Composition/399867"/>
<type value="Composition"/>
<display value="IGBJ Protocol Narrative 5.1"/>
</valueReference>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/narrative-elements">
<valueReference>🔗
<reference value="Composition/399868"/>
<type value="Composition"/>
<display value="IGBJ Protocol Narrative 9"/>
</valueReference>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/protocol-amendment">
<extension url="scope">
<valueCode value="C217026"/>
</extension>
<extension url="country">
<valueCode value="DE"/>
</extension>
<extension url="country">
<valueCode value="GB"/>
</extension>
<extension url="region">
<valueCode value="AU-NSW"/>
</extension>
<extension url="site">
<valueIdentifier>
<system value="https://example.org/site-identifier"/>
<value value="sss"/>
</valueIdentifier>
</extension>
<extension url="approvalDate">
<valueDate value="2017-12-05"/>
</extension>
<extension url="signature">
<valueSignature>
<data
value="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"/>
</valueSignature>
</extension>
<extension url="signatureURL">
<valueString value="https://somelocation"/>
</extension>
<extension url="signatureMethod">
<valueString value="electronic and wet ink copy"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/ResearchStudyStudyAmendmentScopeImpact">
<extension url="scope">
<valueCode value="C41065"/>
</extension>
<extension url="number">
<valuePositiveInt value="234"/>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/ResearchStudyStudyAmendmentScopeImpact">
<extension url="scope">
<valueCode value="C68846"/>
</extension>
<extension url="number">
<valuePositiveInt value="983"/>
</extension>
</extension>
<extension url="primaryReason">
<valueCodeableConcept>
<coding>
<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C218490"/>
<display value="Regulatory Agency Request To Amend"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="secondaryReason">
<valueCodeableConcept>
<coding>
<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C218494"/>
<display value="Manufacturing Change"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="summary">
<valueString value="Regulator required manufacturing chanage."/>
</extension>
<extension url="substantialImpactSafety">
<valueCode value="C49488"/>
</extension>
<extension url="substantialImpactSafetyComment">
<valueString
value="Specifically implemented to decrease safety risks."/>
</extension>
<extension url="substantialImpactReliability">
<valueCode value="C17998"/>
</extension>
<extension url="substantialImpactReliabilityComment">
<valueString value="ccc"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/protocol-amendment-detail">
<extension url="detail">
<valueString value="amendment one"/>
</extension>
<extension url="rationale">
<valueString value="clarification"/>
</extension>
<extension url="section">
<valueCodeableConcept>
<coding>
<system
value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C218515"/>
<display value="1.1 Protocol Synopsis"/>
</coding>
</valueCodeableConcept>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/protocol-amendment-detail">
<extension url="detail">
<valueString value="amendment two"/>
</extension>
<extension url="rationale">
<valueString value="exclude regular drinkers"/>
</extension>
<extension url="section">
<valueCodeableConcept>
<coding>
<system
value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C218550"/>
<display value="5.3 Exclusion Criteria"/>
</coding>
</valueCodeableConcept>
</extension>
</extension>
<extension url="rationale">
<valueString
value="Updates to address safety concern & align with product guidelines."/>
</extension>
<extension url="description">
<valueString
value="Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus has been amended. The new protocol is indicated by Amendment (a) and will be used to conduct the study in place of any preceding version of the protocol. The overall changes and rationale for the changes made to this protocol are as follows: • An exclusion criterion for patients with retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage induced by hypoglycemia. • The GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary of Product Characteristics (2015)."/>
</extension>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper, MD, MSPH"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-sponsor-confidentiality-statement">
<valueString value="All data is confidential"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="registration-submission"/>
<display value="Registration submission"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2018-01-30"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="results-submission"/>
<display value="Results submission"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2019-08-14"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="registration-submission-qc"/>
<display value="Registration submission Quality Check"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2018-01-30"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="results-submission-qc"/>
<display value="Results submission Quality Check"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2019-09-18"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="record-verification"/>
<display value="Record Verification"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<end value="2019-09"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="update-submission"/>
<display value="Update submission"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<end value="2019-09-18"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="registration-posting"/>
<display value="Registration posting"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2018-02-05"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="results-posting"/>
<display value="Results posting"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<start value="2019-10-08"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="primary-outcome-data-collection"/>
<display value="Primary outcome data collection"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<end value="2018-08-20"/>
</valuePeriod>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration">
<extension url="activity">
<valueCodeableConcept>
<coding>
<system
value="http://hl7.org/fhir/research-study-registration-activity"/>
<code value="update-posting"/>
<display value="Update posting"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="actual">
<valueBoolean value="true"/>
</extension>
<extension url="period">
<valuePeriod>
<end value="2019-10-08"/>
</valuePeriod>
</extension>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name
value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
</valueContactDetail>
</extension>
<url value="https://fevir.net/resources/ResearchStudy/399864"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="399864"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<use value="official"/>
<type>
<text value="Regulatory Agency Identifier"/>
</type>
<system value="https://example.org/regulatory-agency-identifier"/>
<value value="NCT03421379"/>
</identifier>
<identifier>
<use value="usual"/>
<type>
<text value="Sponsor Identifier"/>
</type>
<system value="https://example.org/sponsor-identifier"/>
<value value="I8R-JE-IGBJ"/>
</identifier>
<identifier>
<use value="usual"/>
<type>
<text value="Amendment Identifier"/>
</type>
<system value="https://example.org/amendment-identifier"/>
<value value="I8R-JE-IGBJ(a)"/>
</identifier>
<identifier>
<use value="official"/>
<system value="https://clinicaltrials.gov"/>
<value value="NCT03421379"/>
</identifier>
<identifier>
<value value="16962"/>
<assigner>
<display value="Eli Lilly and Company"/>
</assigner>
</identifier>
<identifier>
<type>
<coding>
<system
value="https://clinicaltrials.gov/data-about-studies/study-data-structure#enum-SecondaryIdType"/>
<code value="OTHER"/>
<display value="Other Identifier"/>
</coding>
</type>
<value value="I8R-JE-IGBJ"/>
<assigner>
<display value="Eli Lilly and Company"/>
</assigner>
</identifier>
<version value="(a)"/>
<title
value="A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus"/>
<label>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="short-title"/>
<display value="Short title"/>
</coding>
</type>
<value
value="Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus"/>
</label>
<citeAs
value="A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus [Database Entry: FHIR ResearchStudy Resource]. Contributors: Brian S. Alper, MD, MSPH, Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399864. Revised 2017-12-05. Available at: https://fevir.net/resources/ResearchStudy/399864. Computable resource at: https://fevir.net/resources/ResearchStudy/399864#json."/>
<relatesTo>
<type value="cites"/>
<targetReference>
<type value="Citation"/>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="38444629"/>
</identifier>
<display
value="Seaquist E, Gimenez M, Yan Y, Matsuhisa M, Kao CY, Wadwa RP, Nagai Y, Khunti K. Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials. J Endocr Soc. 2024 Feb 26;8(4):bvae034. doi: 10.1210/jendso/bvae034. eCollection 2024 Feb 19."/>
</targetReference>
</relatesTo>
<relatesTo>
<type value="supported-with"/>
<targetAttachment>
<url value="https://www.clinicalstudydatarequest.com"/>
<title value="IPD Sharing URL"/>
</targetAttachment>
</relatesTo>
<relatesTo>
<type value="documentation"/>
<targetAttachment>
<contentType value="application/pdf"/>
<url
value="https://cdn.clinicaltrials.gov/large-docs/79/NCT03421379/Prot_000.pdf"/>
<size value="684592"/>
<title value="ProtStudy Protocol"/>
<creation value="2017-12-05"/>
</targetAttachment>
</relatesTo>
<relatesTo>
<type value="documentation"/>
<targetAttachment>
<contentType value="application/pdf"/>
<url
value="https://cdn.clinicaltrials.gov/large-docs/79/NCT03421379/SAP_001.pdf"/>
<size value="444216"/>
<title value="SAPStatistical Analysis Plan"/>
<creation value="2018-02-02"/>
</targetAttachment>
</relatesTo>
<date value="2017-12-05"/>
<status value="active"/>
<primaryPurposeType>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type"/>
<code value="treatment"/>
<display value="Treatment"/>
</coding>
</primaryPurposeType>
<phase>
<coding>
<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C15602"/>
<display value="Phase 3"/>
</coding>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
<code value="phase-3"/>
<display value="Phase 3"/>
</coding>
</phase>
<studyDesign>
<text value="Design Masking: None (Open Label)"/>
</studyDesign>
<studyDesign>
<coding>
<system value="https://fevir.net/sevco"/>
<code value="SEVCO:01003"/>
<display value="randomized assignment"/>
</coding>
</studyDesign>
<studyDesign>
<coding>
<system value="https://fevir.net/sevco"/>
<code value="SEVCO:01012"/>
<display value="Crossover cohort design"/>
</coding>
</studyDesign>
<studyDesign>
<coding>
<system value="https://fevir.net/sevco"/>
<code value="SEVCO:01001"/>
<display value="interventional research"/>
</coding>
</studyDesign>
<focus>
<reference>🔗
<reference value="MedicinalProductDefinition/399870"/>
<type value="MedicinalProductDefinition"/>
<display
value="MedicinalProductDefinition submitted as Resource 7 of 7 (399870)"/>
</reference>
</focus>
<condition>
<coding>
<system value="http://snomed.info/sct"/>
<code value="1137328006"/>
<display value="Iatrogenic hypoglycaemia"/>
</coding>
</condition>
<condition>
<text value="Diabetes Mellitus"/>
</condition>
<descriptionSummary
value="The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus."/>
<site>
<reference value="#NCT03421379-Location-0"/>
<type value="Location"/>
</site>
<site>
<reference value="#NCT03421379-Location-1"/>
<type value="Location"/>
</site>
<site>
<reference value="#NCT03421379-Location-2"/>
<type value="Location"/>
</site>
<site>
<reference value="#NCT03421379-Location-3"/>
<type value="Location"/>
</site>
<classifier>
<text value="IPDSharing: Yes"/>
</classifier>
<classifier>
<text
value="IPDSharingDescription: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement."/>
</classifier>
<classifier>
<text value="IPDSharingInfoType: Study Protocol"/>
</classifier>
<classifier>
<text value="IPDSharingInfoType: Statistical Analysis Plan (SAP)"/>
</classifier>
<classifier>
<text value="IPDSharingInfoType: Clinical Study Report (CSR)"/>
</classifier>
<classifier>
<text
value="IPDSharingTimeFrame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting."/>
</classifier>
<classifier>
<text
value="IPDSharingAccessCriteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement."/>
</classifier>
<classifier>
<text value="Has Results: True"/>
</classifier>
<classifier>
<text value="Oversight Classifier: oversightHasDmc False"/>
</classifier>
<classifier>
<text value="Oversight Classifier: isFdaRegulatedDrug True"/>
</classifier>
<classifier>
<text value="Oversight Classifier: isFdaRegulatedDevice False"/>
</classifier>
<classifier>
<text value="Oversight Classifier: isUsExport True"/>
</classifier>
<classifier>
<text value="AgreementPISponsorEmployee: False"/>
</classifier>
<classifier>
<text value="AgreementRestrictionType: GT60"/>
</classifier>
<classifier>
<text value="AgreementRestrictiveAgreement: True"/>
</classifier>
<associatedParty>
<name value="Eli Lilly and Company"/>
<role>
<coding>
<system value="http://hl7.org/fhir/research-study-party-role"/>
<code value="sponsor"/>
<display value="Sponsor"/>
</coding>
</role>
<classifier>
<text value="INDUSTRY"/>
</classifier>
</associatedParty>
<associatedParty>
<name value="Eli Lilly and Company"/>
<role>
<coding>
<system value="http://hl7.org/fhir/research-study-party-role"/>
<code value="lead-sponsor"/>
<display value="Lead sponsor"/>
</coding>
</role>
<classifier>
<text value="INDUSTRY"/>
</classifier>
</associatedParty>
<associatedParty>
<name
value="Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)"/>
<role>
<coding>
<system value="http://hl7.org/fhir/research-study-party-role"/>
<code value="study-chair"/>
<display value="Study chair"/>
</coding>
</role>
<party>
<display value="Eli Lilly and Company"/>
</party>
</associatedParty>
<progressStatus>
<state>
<coding>
<system value="http://hl7.org/fhir/research-study-status"/>
<code value="completed"/>
<display value="Completed"/>
</coding>
</state>
</progressStatus>
<progressStatus>
<state>
<coding>
<system value="http://hl7.org/fhir/research-study-status"/>
<code value="overall-study"/>
<display value="Overall study"/>
</coding>
</state>
<actual value="true"/>
<period>
<start value="2018-02-21"/>
<end value="2018-08-20"/>
</period>
</progressStatus>
<recruitment>
<actualNumber value="75"/>
<eligibility>
<reference value="Group/267225"/>
<type value="Group"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379 Eligibility Criteria"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="NCT03421379 Eligibility Criteria"/>
</eligibility>
</recruitment>
<comparisonGroup>
<eligibility>
<reference value="#NCT03421379-comparison-group-0"/>
<type value="Group"/>
<display
value="Glucagon Nasal Powder: A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally."/>
</eligibility>
</comparisonGroup>
<comparisonGroup>
<eligibility>
<reference value="#NCT03421379-comparison-group-1"/>
<type value="Group"/>
<display
value="Glucagon Hydrochloride Solution: A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)"/>
</eligibility>
</comparisonGroup>
<objective>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="primary"/>
<display value="Primary"/>
</coding>
</type>
<outcomeMeasure>
<name
value="Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="primary"/>
<display value="Primary"/>
</coding>
</type>
<description
value="Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (≥) 70 milligrams per deciliter (mg/dL) or an increase of ≥20 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration."/>
<endpoint>
<reference value="EvidenceVariable/267226"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-primaryOutcome-0"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
</objective>
<objective>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<outcomeMeasure>
<name
value="Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<description
value="PD assessment measured the change from Baseline in maximal blood glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride intramuscular (IM)."/>
<endpoint>
<reference value="EvidenceVariable/267227"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-secondaryOutcome-0"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
<outcomeMeasure>
<name
value="PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<description
value="PD assessment measured the time to maximal concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM."/>
<endpoint>
<reference value="EvidenceVariable/267228"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-secondaryOutcome-1"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
<outcomeMeasure>
<name
value="Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<description
value="PK assessment measured the change from baseline in the area under the concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration of Glucagon Nasal Powder and Glucagon Hydrochloride IM."/>
<endpoint>
<reference value="EvidenceVariable/267229"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-secondaryOutcome-2"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
<outcomeMeasure>
<name
value="PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<description
value="PK assessment measured the change from baseline in maximal concentration (Cmax) of glucagon nasal powder and glucagon hydrochloride IM."/>
<endpoint>
<reference value="EvidenceVariable/267230"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-secondaryOutcome-3"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
<outcomeMeasure>
<name
value="PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM"/>
<type>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
<code value="secondary"/>
<display value="Secondary"/>
</coding>
</type>
<description
value="PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM."/>
<endpoint>
<reference value="EvidenceVariable/267231"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379-secondaryOutcome-4"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
</endpoint>
</outcomeMeasure>
</objective>
<result>
<reference value="Composition/267224"/>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="NCT03421379 Results Report"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="Results Section for NCT03421379"/>
</result>
</ResearchStudy>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-25
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change